Cybin Inc. Shares Commence Trading on the OTCQB Venture Market on March 8, 2021
March 08 2021 - 07:21AM
InvestorsHub NewsWire
TORONTO, Canada -- March 8, 2021 -- InvestorsHub NewsWire
-- Cybin Inc. (NEO:CYBN) (OTCQB:CLXPF) ("Cybin" or the
"Company"), a biotechnology company focused on progressing
psychedelic therapeutics, today announced that its shares commence
trading on the OTCQB® Venture Market (the
"OTCQB") on March 8, 2021, under the symbol "CLXPF."
The OTCQB, operated by OTC Markets Group Inc., is designed for
developing and entrepreneurial companies in the United States and
abroad. Companies must be current in their financial reporting and
undergo an annual verification and management certification
process, including meeting a minimum bid price and other financial
conditions. With more compliance and quality standards, the OTCQB
provides investors improved visibility to enhance trading
decisions. The OTCQB is recognized by the United States Securities
and Exchange Commission as an established public market providing
public information for analysis and value of securities.
"With the commencement of trading on the OTCQB, Cybin has
achieved another important milestone on its path to advancing
mental health care through evidenced-based therapeutics. This
additional capital markets exposure offers us greater visibility
within the investment community, which should enhance our liquidity
and increase our access to institutional and retail investors. This
support is extremely valuable to us as we continue to progress our
psychedelic drug development programs that target mental health
disorders, such as Major Depressive Disorder, and other
therapy-resistant psychiatric disorders," stated Doug Drysdale, CEO
of Cybin.
Cybin will continue to trade on the NEO Exchange under its
existing symbol "CYBN."
About Cybin
Cybin is a leading biotechnology company focused on progressing
psychedelic therapeutics by utilizing proprietary drug discovery
platforms, innovative drug delivery systems, novel formulation
approaches and treatment regimens for psychiatric disorders.
Cautionary Notes and Forward-Looking Statements
Certain statements in this news release related to the Company
are forward-looking statements and are prospective in nature.
Forward-looking statements are not based on historical facts, but
rather on current expectations and projections about future events
and are therefore subject to risks and uncertainties which could
cause actual results to differ materially from the future results
expressed or implied by the forward-looking statements. These
statements generally can be identified by the use of
forward-looking words such as "may", "should", "could", "intend",
"estimate", "plan", "anticipate", "expect", "believe" or
"continue", or the negative thereof or similar variations.
Forward-looking statements in this news release include statements
regarding enhanced liquidity, the value of additional capital
markets exposure, access to institutional and retail investors, the
Company's new strategic brand messaging campaign, and psychedelic
drug development programs to potentially treat mental health
disorders. There are numerous risks and uncertainties that could
cause actual results and Cybin's plans and objectives to differ
materially from those expressed in the forward-looking information.
Actual results and future events could differ materially from those
anticipated in such information. These and all subsequent written
and oral forward-looking information are based on estimates and
opinions of management on the dates they are made and are expressly
qualified in their entirety by this notice. Except as required by
law, the Company does not intend to update these forward-looking
statements.
Cybin makes no medical, treatment or health benefit claims about
Cybin's proposed products. The U.S. Food and Drug Administration,
Health Canada or other similar regulatory authorities have not
evaluated claims regarding psilocybin, psychedelic tryptamine,
tryptamine derivatives or other psychedelic compounds or
nutraceutical products. The efficacy of such products have not been
confirmed by approved research. There is no assurance that the use
of psilocybin, psychedelic tryptamine, tryptamine derivatives or
other psychedelic compounds or nutraceuticals can diagnose, treat,
cure or prevent any disease or condition. Vigorous scientific
research and clinical trials are needed. Cybin has not conducted
clinical trials for the use of its proposed products. Any
references to quality, consistency, efficacy and safety of
potential products do not imply that Cybin verified such in
clinical trials or that Cybin will complete such trials. If Cybin
cannot obtain the approvals or research necessary to commercialize
its business, it may have a material adverse effect on Cybin's
performance and operations.
The NEO Exchange has neither approved nor disapproved the
contents of this news release and is not responsible for the
adequacy and accuracy of the contents herein.
Contacts
Investor Contacts:
Tim Regan/Scott Eckstein
KCSA Strategic Communications
Cybin@kcsa.com
Lisa M. Wilson
In-Site Communications, Inc.
lwilson@insitecony.com
Media Contacts:
John Kanakis
Cybin Inc.
John@cybin.com
Annie Graf
KCSA Strategic Communications
agraf@kcsa.com
Faith Pomeroy-Ward
In-Site Communications, Inc.
Faith@insitecony.com
Cybin (AMEX:CYBN)
Historical Stock Chart
From Feb 2024 to Mar 2024
Cybin (AMEX:CYBN)
Historical Stock Chart
From Mar 2023 to Mar 2024